rheumatoid arthritis
Exagen, Emory University to Study of Long-Term Effects of COVID-19 on Autoimmune Disease
The study will evaluate the emergence of biomarkers that are indicators for autoimmune diseases and assess these biomarkers in mild and moderate COVID-19 patients.
Scipher Medicine Raises $82M in Series C Financing
Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.
Myriad Genetics to Sell Vectra DA Business, Reorganize International Presence
The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs.Â
Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
Scipher Medicine to Launch PrismRA Anti-TNF Response Predictor Following Positive Data Publication
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.